Manufacturing costs of HPV vaccines for developing countries  by Clendinen, Chaevia et al.
Vaccine 34 (2016) 5984–5989Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vaccineManufacturing costs of HPV vaccines for developing countrieshttp://dx.doi.org/10.1016/j.vaccine.2016.09.042
0264-410X/ 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
⇑ Corresponding author.
E-mail addresses: csclendi@gmail.com (C. Clendinen), yapei.zhang@yale.edu
(Y. Zhang), rnwarbur@uvic.ca (R.N. Warburton), lightdo@rowan.edu (D.W. Light).Chaevia Clendinen a, Yapei Zhang b, Rebecca N. Warburton c, Donald W. Light d,⇑
aDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
bA.B. Yale School of Medicine, 333 Cedar St, New Haven, CT 06510, USA
c School of Public Administration, University of Victoria, Victoria, BC V8W 2Y2, Canada
dDepartment of Psychiatry, Rowan University School of Osteopathic Medicine, 2250 Chapel Avenue, Cherry Hill, NJ 08002, USAa r t i c l e i n f o
Article history:
Received 29 June 2016
Received in revised form 19 September
2016
Accepted 20 September 2016
Available online 19 October 2016
Keywords:
Vaccine
Manufacturing cost
Gavi
Human papillomavirus
Affordability
Accessa b s t r a c t
Background: Nearly all of the 500,000 new cases of cervical cancer and 270,000 deaths occur in middle or
lower income countries. Yet the two most prevalent HPV vaccines are unaffordable to most. Even prices
to Gavi, the Vaccine Alliance, are unaffordable to graduating countries, once they lose Gavi subsidies.
Merck and Glaxosmithkline (GSK) claim their prices to Gavi equal their manufacturing costs; but these
costs remain undisclosed. We undertook this investigation to estimate those costs.
Methods: Searches in published and commercial literature for information about the manufacturing of
these vaccines. Interviews with experts in vaccine manufacturing.
Findings: This detailed sensitivity analysis, based on the best available evidence, finds that after a first set
of batches for affluent markets, manufacturing costs of Gardasil for developing countries range between
$0.48 and $0.59 a dose, a fraction of its alleged costs of $4.50. Because volume of Cervarix is low, its per
unit costs are much higher, though at comparable volumes, its costs would be similar.
Interpretation: Given the recovery of fixed and annual costs from sales in affluent markets, Merck’s break-
even price to Gavi could be $0.50–$0.60, not $4.50. These savings could support Gavi programs to
strengthen delivery and increase coverage. Outside Gavi, prices to lower- and middle-income countries,
with profit, could also be lowered and made available to millions more adolescents at risk. These esti-
mates and their policy implications deserve further discussion.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Cervical cancer is the second most common cancer in females,
with over 500,000 new cases per year worldwide. Approximately
85% of these new cases and over 90% of the 270,000 deaths from
cervical cancer occur in lower- and middle-income countries,
where cervical cancer remains a leading cause of death [1,2].
Human papillomavirus (HPV) infection is linked to >99% of cervical
cancers [3]. While infection with most strains of HPV are transient
and benign, 16 HPV strains are linked to cancerous and precancer-
ous lesions in the genital and oral areas [4,5]. HPV-16 and -18 are
associated with 70% of invasive cervical cancers worldwide, as well
as cancer of the vulva, vagina, anus, and throat [6,7].
Two vaccines were developed to prevent HPV-16/18 related
cancers. The quadrivalent HPV recombinant vaccine called
Gardasil-4 and the bivalent HPV vaccine called Cervarix were
developed by Merck and GlaxoSmithKline (GSK) respectively.Although Merck has subsequently developed Gardasil-9,
Gardasil-4 and Cervarix remain widely used and are supplied by
contract to Gavi, the Vaccine Alliance (Gavi), a public private part-
nership that provides financial subsidies to accelerate the intro-
duction of new and under-utilized vaccines in the poorest
countries of the world.
Gardasil-4 consists of four virus-like particles derived from HPV
types 6, 11, 16 and 18. Cervarix consists of two virus-like particles
derived from HPV types 16 and 18. When administered before sex-
ual activity, these vaccines are 99 percent effective in preventing
associated cancers [8]. Gardasil-4 also protects against genital
warts associated with HPV-6 and -11 [9] and may induce cross-
protection against oncogenic serotypes HPV-31 and -45 [10]. In
2009, the World Health Organization (WHO) recommended both
HPV vaccines for girls aged 9–13, which Gavi promptly adopted
[11]. As of 2015, WHO now recommends two doses of these vacci-
nes, spaced 6–12 months apart, for girls aged 9–13 [12].
As the first vaccines against HPV-related cancers, the retail
prices for Gardasil-4 and Cervarix were high, at US$150–$190
per dose. Negotiated prices to third parties are usually undisclosed.
The lowest known prices outside Gavi are US$12.83 for Gardasil-4
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vaccines have been licensed in over 100 countries, several factors
have contributed to low uptake [13–15]. Chief among these factors
is the price of the vaccines [14].
In 2013, Merck offered to sell Gardasil to Gavi for US$4.50, and
the President of Merck Vaccines said, ‘‘The price is what we calculate
to be our cost of goods. As we expand volumes, the cost per unit can go
down. Our intent is to sell it to Gavi at a price that does not bring profit
to Merck.” She made it clear that manufacturing costs do not
include research and other costs. [16]. GSK made similar state-
ments and offered Cervarix for $4.60 a dose. Since neither manu-
facturer provided evidence of its cost of goods, this study was
undertaken to determine what they are and how they vary by vol-
ume. Determining these closely held costs is difficult, and few
detailed studies have been published [17]. This study presents
the first detailed cost estimate of the complex manufacturing pro-
cess of new-generation vaccines Gardasil-4 and Cervarix. It pro-
vides important insights into global price barriers and a useful
framework for research and decisions concerning accessible pric-
ing. Its limitations underscore the need for greater transparency
in vaccine pricing.2. Methods
We searched the published, grey, commercial, and company lit-
erature for information pertinent to the manufacturing and costs of
these vaccines. We used Scopus, Web of Science, PubMed, Pro-
quest, Factiva and Bloomberg, using various combinations of these
search terms: vaccine, production, manufacturing, cost, and costs.
Company reports and past press releases were also helpful. We
also identified experts in manufacturing through our contacts
and authors of pertinent reports, talks or articles. We gained
insights from corresponding and interviewing some of them. Costs
fall into four categories: fixed annualized capital costs of building,
pipes, equipment, and Good Manufacturing Practices (GMP) quali-
fications; two kinds of variable costs, annual costs for labor and
per-batch costs for raw materials and filling and packaging the
vials; and factory overheads (indirect costs). In accordance with
standard accounting practices for estimating costs of manufactur-
ing, other costs are not included such as research and development
(R&D), marketing, or general administration and legal services [17–
19]. In particular, R&D to discover and develop a drug or vaccine
are widely regarded as sunk costs and not part of manufacturing
costs, as the President of Merck Vaccines, experts cited here, and
the UNIDO Manual over its many editions state [20]. R&D costs
after a product is approved reflect investment decisions on using
profits from sales to improve, upgrade, extend, or expand on that
product for further sales. Brief summaries of the major categories
of expense are given here. See Appendix A (details on manufactur-
ing cost estimates) for further details.2.1. Annualized capital costs
Annualized capital costs estimate the cost of replacing manu-
facturing facilities, which include buildings, pipes, equipment,
lines and GMP (Good Manufacturing Practices) up to beginning
production. Following accepted accounting and economic evalua-
tion practices [17,18], equipment constitutes about one-third of
total cost. Annualized capital costs assume a 5% real (no-
inflation) discount rate, 10 years of useful life for the equipment,
and 25 years of useful life for the building [17].
For sensitivity analysis, as described in Appendix A, capital costs
were estimated based on the share of the total manufacturing com-
plex used for Gardasil or Cervarix, at most one quarter of the total
complex cost. For Gardasil, one quarter of the $1 billion spent byMerck in building its manufacturing complex in Durham, NC was
used as the high estimate; a 20% discount, or $200 million for the
middle estimate; and a 40% discount, or $150 million for the low
estimate. For Cervarix, one quarter of the $830 million spent by
GSK in building its manufacturing complex in France was used as
the high estimate; a 20% discount, or $166 million for the middle
estimate; and a 40% discount, or $124.5 million for the low esti-
mate. Thus the low, middle, and high annualized capital costs to
replace all buildings and equipment associated with manufactur-
ing Gardasil-4 are $12.9 million, $17.2 million, and $21.5 million
respectively. The low, middle, and high annualized capital costs
for manufacturing Cervarix are $10.7 million, $14.3 million, and
$17.9 million respectively.
2.2. Vaccine yield
The number of doses that can be made from a given batch pro-
duced with the raw materials and equipment critically affects cost.
As explained in Appendix A, the yield for Gardasil-4 is estimated to
be 29 mg/L, and for Cervarix 40 mg/L. The Gardasil-4 vaccine
consists of a 0.5 mL vial containing 20 Âlg each of HPV-6 L1 and
HPV-18 L1 virus-like particles (VLPs) protein, and 40 Âlg each of
HPV-11 and HPV-16 L1 VLPs protein [21]. Thus two ‘‘batches” of
11 and 16 must be manufactured to match up with the yield from
one batch of 6 and 18. These 6 batches are called a set. For reasons
explained in Appendix A, a ‘‘set” is estimated to yield 15.4 million
doses. Cervarix, 0.5 mL vial, contains 20 Âlg each of HPV-16 and
HPV-18 L1 VLP proteins [22]. For reasons explained in Appendix
A, two batches are estimated to yield a set of 3.6 million doses.
2.3. Raw materials
Based on information made public by Merck and GSK or other
sources, we researched in detail the materials, quantities, costs,
and patterns of use or reuse needed to manufacture each vaccine
(See Appendix A). Actual costs vary by brand and bulk-order dis-
counts. For Gardasil-4, this analysis estimates that the retail costs
for all material to manufacture a set of 15.4 million doses are
approximately $2.9 million. For Cervarix, the high estimate for
materials for 3.6 million doses is approximately $1.27 million. For
our sensitivity analysis, we again assumed that large buyers nego-
tiate discounts of 20–40% and used these for the middle and low
estimates. These produce a middle estimate of $2.37 million and
a low estimate of $1.78 million for Gardasil-4, and $1.02 million
and $0.76 million for Cervarix.
2.4. Manufacturing personnel
Based on in-depth studies of other vaccines and specific reports
for Gardasil-4 and Cervarix, it appears that both Merck and GSK
have approximately 152 personnel involved in manufacturing their
vaccines [21]. Staff for manufacturing, quality assurance, and qual-
ity control (QA-QC) to GMP standards, filling & packaging, and
supervision are included in these estimates and reflect industry
and independent information. They are paid on annual salaries,
and we estimate the costs of personnel for Gardasil-4 to range
between $7.99 and $11.22 million a year and for Cervarix between
$6.37 and $8.95 million. (Compensation in France differs from the
U.S. See Appendix A.) For the analysis, we used the average of these
estimated annual costs for a middle estimate, $9.0 million for
Gardasil-4 and $7.2 for Cervarix.
2.5. Factory and administrative overheads
Based on other studies of manufacturing cost [17,18], factory
and administrative overhead costs equal 45 percent of the cost
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Fig. 1. Cost of manufacturing first 15.4 M and second 15.4 M doses of Gardasil in
single-fill vials.
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4’s low, middle, and high costs at $4.39, $5.12, and $6.38 million.
For Cervarix, the cost estimates are $3.21, $3.69, and $4.59 million.
2.6. Filling and packaging
According to confidential interviews with experts on manufac-
turing, the wholesale unit cost of the vial, cap, and stopper for
single-dose packaging is $0.21 per dose plus $0.10 for secondary
packaging materials, for a total of $4.77 million for 15.4 million
doses of Gardasil-4 and $1.12 million for 3.6 million doses of Cer-
varix. The fill/pack staff are included in personnel, and indirect
costs are part of overheads. There is no indication that the dis-
counts for these vials themselves are substantial.
3. Results
The estimated low, middle, and high costs of manufacturing per
dose is the sum of the total cost divided by volume of doses within
a fiscal year. As Table 1 shows, the estimated manufacturing cost
for Gardasil-4 ranges from US$2.07 to $3.05 per dose. Manufactur-
ing a second set of 15.4 million doses within a year costs $0.48–$0.
59 per dose because fixed capital costs and annual personnel costs
are included in the first set (Table 2). Because filling and packaging
constitute 58.2% of total costs in the second set, manufacturing the
vaccine in ten-dose vials would lower the cost per dose to around
$0.21 a dose, or $0.42 for a two-dose course per person (Table 2).
Fig. 1 shows the average costs per dose of the first and second sets
from Tables 1 and 2. Because per unit costs decline as volume
increases, the most important factor in reducing vaccine costs is
not a technological breakthrough but ‘‘a major increase in
procurement. . .” [18]. This is illustrated in Fig. 2. As shown in
Appendix B (worldwide sales and profits), Merck’s sales have
steadily risen since 2010 to more than 21 million doses a year.
For Cervarix, the estimated manufacturing costs in the first set
of 3.6 million doses ranges from $6.16 to $9.39 a dose in single-Table 1
Estimated costs for producing the first set of 15.4 M doses of Gardasil-4 (2014 million
US$).
Low
estimate
Middle
estimate
High
estimate
Annualized capital costs $12.92 $17.23 $21.54
Raw materials 1.78 2.37 2.96
Labor 7.99 9.00 11.22
Factory and administrative
overheads
4.39 5.12 6.38
Filling and packaging,
single-dose vials
4.77 4.77 4.77
Total costs 31.85 38.48 46.87
Dollars per dose, single-fill 2.07 2.50 3.05
Dollars per dose, 10-fill 0.81 0.98 1.19
Table 2
Estimated costs for producing the second set of 15.4 M doses of Gardasil-4
(2014 million US$).
Low
estimate
Middle
estimate
High
estimate
Raw materials 1.78 2.37 2.96
Factory and administrative
Overheads
0.80 1.07 1.33
Filling and packaging,
single-dose vials
4.77 4.77 4.77
Total costs 7.34 8.20 9.06
Dollars per dose, single-fill 0.48 0.53 0.59
Dollars per dose, 10-fill 0.19 0.21 0.23dose vials. Table 3 indicates that the average costs per single dose
in the second set produced within a fiscal year would drop to US$0.
62–$0.82 for single-fill vials. Ten-dose vials would cost $0.24–$0.
32 per dose.
Fig. 3 shows the average costs per dose of the first and second
sets from Tables 3 and 4. As shown in Appendix B, GSK appears
to have sold about 2.1 million doses in 2015, substantially fewer
than one set. If first-set costs were attributed to just this volume,
the per-unit cost would jump to $10.56–$16.10.4. Discussion
Based on the best available information from public sources,
company reports, and interviews with experts, this study uses sen-
sitivity ranges to estimate the manufacturing costs of Gardasil-4
and Cervarix. For the first set of 15.4 million doses of Gardasil-4,
manufacturing costs lie between US$2.07 and $3.05. Manufactur-
ing costs for a second set are about US$0.48–$0.59 per dose. These
estimates are well below the price of US$4.50 given to Gavi by
Merck.
For this study, an analysis of sales, volume and profits was car-
ried out and is reported in Appendix B. Merck has enjoyed substan-
tial sales and gross profits. From 2006 to 2015, Merck took in about
US$13.7 billion from sales of Gardasil-4. Its gross profits more than
match any reasonable estimate of past corporate research and
development costs incurred for this vaccine, net of taxpayer subsi-
dies [23,24]. Since 2010, Merck’s sales have steadily risen to more
than 21 million doses in 2015; so the manufacturing costs for the
Table 3
Estimated costs for producing the first set of 3.6 M doses of Cervarix (2014 million
US$).
Low
estimate
Middle
estimate
High
estimate
Annualized capital costs $10.73 $14.30 $17.88
Raw materials 0.76 1.02 1.27
Labor 6.37 7.17 8.95
Factory and administrative
overheads
3.21 3.69 4.59
Filling and packaging,
single-dose vials
1.12 1.12 1.12
Total costs 22.19 27.30 33.81
Dollars per dose, single-fill 6.16 7.58 9.39
Dollars per dose, 10-fill 2.40 2.96 3.66
Fig. 2. Gardasil cost per dose for first and second sets.
Table 4
Estimated costs for producing the second set of 3.6 M doses of Cervarix (2014 million
US$).
Low
estimate
Middle
estimate
High
estimate
Raw materials 0.76 1.02 1.27
Factory and administrative
overheads
0.34 0.46 0.57
Filling and packaging,
single-dose vials
1.12 1.12 1.12
Total costs 2.22 2.60 2.96
Dollars per dose, single-fill 0.62 0.72 0.82
Dollars per dose, 10-fill 0.24 0.28 0.32
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$0.48–$0.59 per dose. Ten-dose vials could lower costs further.
The estimated manufacturing costs of Cervarix for the first set
lie between US$6.16 and $9.39 which is well above the price to
Gavi. Appendix B shows that from 2006 to 2015, GSK received
gross revenues of about US$2.9 billion from Cervarix sales. Its gross
profits of $2.6 billion more than covered its past, net corporate
costs for research and development. Outside its contract to Gavi,
GSK has the most to gain by competing on price against Merck
for market share. Thus, even with only two companies, lively pricecompetition could take place. This would make HPV vaccines more
accessible, as happened when competition lowered prices for the
first generation of HIV-AIDS drugs [25].
Gavi’s leadership has been criticized for not investigating real
manufacturing costs and bargaining for lower prices that would
be sustainable for its countries [26]. In our view, Gavi and Merck
leaders need to re-price Gardasil-4 at $0.59 or less. While Gavi
emphasizes vaccine introductions [27], it appears to be meeting lit-
tle of the overall demand from member countries, which is esti-
mated to rise to 39 million doses a year by 2020 [28,29]. A price
at manufacturing cost would greatly increase Gavi’s capacity to
vaccinate more children.
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Fig. 3. Cost of manufacturing first 3.6 M and second 3.6 M doses of Cervarix in
single-fill vials.
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burden of HPV cancers and loss of productivity in the prime of life
have hardly been touched. In the 33 countries where HPV vaccines
are likely to have the greatest benefit, only 4 had introduced
national vaccination programs as of January 2012 [2]. Agosti and
Goldie estimated a decade ago that ‘‘with every 5-year delay in
bringing [HPV] vaccination to developing countries, 1.5 million to
2 million more women will die.” [14].
Setting low vaccine prices for Gavi-eligible countries is an
important moral commitment by the companies to reduce global
health inequities by preventing cancer and deaths in lower-
income countries. Merck and GSK have discount and charitable
programs that increase access to their HPV vaccines for some coun-
tries. Both companies rank high in the global Access to Medicines
Index: GSK ranks first and Merck sixth in the world. Both are strong
supporters of Gavi. As producers of global public health goods, they
need to be transparent about their costs and negotiate prices
accordingly. For countries just above the threshold income for Gavi
subsidies, the lowest world prices of $12–13 per dose are much
higher than what scores of those countries can afford. As Agosti
and Goldie wrote, for lower-income countries, ‘‘. . .per-dose cost
may need to be as low as $1 to $2. . .” [14]. This study challenges
the manufacturers and Gavi to commence vigorous discussion
about how to achieve such prices now and lower prices in the
future.5. Limitations
This analysis has several limitations. While it is based on the
best available information, the lack of access to verifiable manufac-turing information from the companies has prevented more accu-
rate figures. The high, middle, and low ranges are estimates, and
actual costs will depend on the details of each variable in our esti-
mates, such as the manufacturing site, details of manufacturing,
the costs of GMP, the number and costs of personnel needed to
make each vaccine, and fluctuations in costs of raw materials. This
analysis is limited to the two HPV vaccines used by Gavi, and much
work is underway to develop cheaper HPV vaccines that are better
suited to the realities of vaccination in developing countries.Authors’ contributions
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